CFO Sells 39,120 MoonLake Immunotherapeutics Shares Worth ~$862,000 On June 22, Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics (NASDAQ:MLTX), sold 39,120 common shares in an open-market transaction valued at approximately $862,000, as disclosed in…
e SEC Form 4 filing. Transaction summary Transaction value based on SEC Form 4 reported price ($22.04); post-transaction value based on June 22 market close ($22.16)
Key questions – What proportion of Bodenstedt’s MoonLake Immunotherapeutics stake was involved in this transaction? The sale represented 3.4% of direct holdings at the time, leaving a substantial direct ownership position of over 1.1 million shares after the transaction. – Did the transaction involve any indirect holdings or derivative instruments? No; all shares sold were held directly, with no indirect entities, trusts, or option exercises involved, and Bodenstedt’s indirect and derivative holdings remain at zero post-transaction.
Company overview Company snapshot MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on novel immunotherapeutic solutions for inflammatory diseases. The company leverages its proprietary Nanobody platform to address significant unmet medical needs in immunology. Its strategy centers on advancing differentiated assets through clinical development to build a competitive edge in the inflammatory disease market. – MoonLake Immunotherapeutics is advancing Sonelokimab, an investigational Nanobody-based therapy in Phase II trials targeting inflammatory diseases such as hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis. – The company operates a clinical-stage biopharmaceutical model, generating value through drug development and potential future licensing or commercialization of its lead candidate. – Primary customers are anticipated to be healthcare providers and specialists treating patients with chronic inflammatory conditions.